PREVENTION OF HEPATOTOXICITY OF VALPROIC ACID WITH CONCOMITANT SUPPLEMENT OF CARNITINE: AN EXPERIMENTAL STUDY IN ALBINO RATS

Syed Khanzada Khan, Shahida Tasleem, Naila Ismail, Purdil Khan, Kazi Abdul Shakoor

Abstract


Background: Valproic acid is an antiepileptic drug which may cause carnitine deficiency and subsequently hepatotoxicity in the form of necrosis and steatosis. The objective of this study was to observe the protective role of carnitine against valproic acid induced hepatotoxicity in albino rats.
Material & Methods: This was an experimental study of concurrent parallel design in albino rats, carried out in Department of Pathology, Basic Medical Sciences Institute, Jinnah Postgraduate Medical Centre, Karachi. Thirty adult and apparently healthy albino rats were selected. The animals were divided into five equal groups; Group A control, kept on the diet of animal house only, Group B treated with therapeutic doses of valproic acid + carnitine supplement, group C treated with toxic doses of valproic acid + carnitine supplement, Th group treated with therapeutic doses of valproic acid and Tx group treated with toxic doses of valproic acid. All the animals were fed on routine diet of animal house and sacrificed after 3 weeks of treatment. The liver of each animal was properly fixed, sectioned, processed, stained with H&E stain and seen under light microscope.
Results: No significant changes in the livers were seen in group A. Focal necrosis could be seen in the liver of one out of six animals (16.66%) of group B, foci of steatosis were seen in one (16.66%) and necrosis in 3(50%) animals of group C whereas in Th group steatosis was seen in 5(83.33%) and necrosis in one (16.66%) and in Tx group steatosis in 5(83.33%) and necrosis in 2(33.33%).
Conclusion: Valproic acid induced hepatotoxicity in the form of steatosis can be prevented by carnitine supplement in albino rats.

Keywords


Valproic acid; Carnitine; Hepatotoxicity; Albino rats

Full Text:

PDF

References


Johannessen CU, Johannessen SI. Valproate:

past, present, and future. CNS Drug Rev 2003; 9:

-216.

Rosenberg G. The mechanisms of action of valproate

in neuropsychiatric disorders: can we see

the forest for the trees? Cell Mol Life Sci 2007; 64:

-103.

Watkins PB, Seeff LB. Drug-induced liver injury:

summary of a single topic clinical research conference.

Hepatology 2006; 43: 618-31.

Spiller HA, Krenzelok EP, Klein-Schwartz W, Winter

ML, Weber JA, Sollee DR, et al. Multicenter

case series of valproic acid ingestion: serum

concentrations and toxicity. J Toxicol Clin Toxicol

; 38: 755-60.

Andersen GO, Ritland S. Life threatening intoxication

with sodium valproate. J Toxicol Clin Toxicol

; 33: 279-84.

Borum PR, Bennett SG. Carnitine as an essential

nutrient. J Am Coll Nutr 1986; 5: 177-82.

Scaglia F. Longo N. Primary and secoudary alterations

of neonatal carnitine metalboism. Semin

Perinatol 1999; 23: 152-61.

Matsubara M, Ishihara T, Takeyama N, Tanaka

T. Valproic acid overdose and L-carnitine therapy.

J Anal Toxicol 1996; 20: 55-8.

Matsuda I, Ohtani Y. Carnitine status in Reye and

Reye-like syndromes. Pediatr Neurol 1986; 2:

-4.

Raskind JY, El-Chaar GM. The role of carnitine

supplementation during valproic acid therapy.

Ann Pharmacother 2000; 34: 630-8.

De Vivo DC, Bohan TP, Coulter DL. Dreifuss

FE, Greenwood RS, Nordli DR, et al. L-carnitine

supplementation in childhood epilepsy: current

perspectives. Epilepsia 1998; 39: 1216-25.

LheureuxPE, Hantson P. Carnitine in the tratment

of valpric acid-induced toxicity. Clin Toxicol (Philer)

; 47: 101-11.

Chen G, Bohner B, Enser CR. Evaluation of five

methods for testing anticonvulsant ativities. Pros

Soci Exp Bio Med 1956; 334-9.

Matsubara M, Ishihara T, Takeyama N, Tanaka

T. Valproic acid overdose and L-carnitine therapy.

J Anal Toxicol 1996; 20: 55-8.

DeVivo DC. Effect of L-carnitine treatment for valproate-

induced hepatotoxicity. Neurology 2002;

: 507-8.

Kato A. Carnitine deficiency with valproate sodium

therapy - the difference by normal diet and enteral

nutrition. No To Hattatsu 2013; 45: 17-20.

Xiong H, Liu CT, Zhang YH, Bao XH, Jiang YW,

Zhao H, et al. Valproic acid-induced idiosyncratic

liver injury in 4 cases. Zhonghua Er Ke Za Zhi

; 50: 890-4.

Nishida N, Sugimoto T, Araki A, Woo M, Shakano

Y, Kobayashi Y. Carnitine metabolism in valprovate

treated rats: the effect of L-carnitine supplementation.

Pediatr Res 1987; 22: 500-3.

Fujimiya T, Abbott FS. Fluorinated analogues as

mechanistic probes in valproic acid hepatotoxicity:

hepatic microvesicular steatosis and glutathione

status. Chem Res Toxicol 1995; 8: 671-82.

Laub MC, Paetzke-Brunner I, Jaeger G. Serum

carnitine during valproic acid therapy. Epilepsia

; 27: 559-62.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Syed Khanzada Khan, Shahida Tasleem, Naila Ismail, Purdil Khan, Kazi Abdul Shakoor

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.